Skip to main content

Table 2 Baseline demographic characteristics according to follow-up groups

From: The effect of stimulation therapy and donepezil on cognitive function in Alzheimer’s disease. A community based RCT with a two-by-two factorial design

Groups

Age ± SD*

Gender

Education

Living

  
  

Female

≤ 7 yerars

Couple

Comorbidity

Drug use

  

n (%)

n (%)

n (%)

± SD*

± SD*

Municipality

      

Stimulation

81.6 ± 6.7

59(57)

88(85)

48(46)

1.82 ± 1.7

4.89 ± 3.3

Standard care

4.89 ± 3.3

54(65)

65(79)

37(45)

1.65 ± 1.1

5.40 ± 3.9

p-value

0.12

0.25

0.34

0.83

0.45

0.34

Drug

      

Donepezil

80.80 ± 6.8

62(67)

82(89)

39(42)

1.90 ± 1.7

5.10 ± 3.3

Placebo

80.85 ± 7.3

50(54)

70(75)

46(49)

1.59 ± 1.2

5.16 ± 3.8

p-value

0.96

0.07

0.014

0.30

0.15

0.90

Combination

      

Donepezil + stimulation

81.32 ± 7.0

31(60)

47(90)

28(54)

2.02 ± 2.0

4.92 ± 2.8

Placebo + Standard care

79.81 ± 8.1

22(54)

29(71)

19(46)

1.51 ± 1.1

5.41 ± 3.9

p-value

0.34

0.57

0.015

0.47

0.14

0.48

Head to head

      

Stimulation therapy

81.89 ± 8.3

27(53)

40(78)

24(47)

1.61 ± 1.4

4.88 ± 3.7

Donepezil

80.17 ± 6.4

28(74)

32(86)

15(39)

1.76 ± 1.3

5.26 ± 4.0

p-value

0.21

0.046

0.33

0.45

0.61

0.65

  1. *Mean values ± standard deviation.